A method for providing a solid amorphous HMO product, said method including drying an aqueous composition of said HMO. Solid amorphous HMO product is obtained via said method, as well as solid amorphous HMO product per se.
The present invention relates to a yeast extract comprising free glutamate in an amount of at least 7 wt. % on salt free dry matter and comprising an amount of 5′-ribonucleotides of at least 10 wt. % on salt free dry matter.
The present invention relates to cosmetic composition comprising UV-filter(s), an ester of a fatty acid and dextrin and a mixture of branched and linear saturated C15-C19, wherein said mixture comprised primarily branched saturated C15-C19 and a specific cellulose derivative. This cosmetic composition shows a significantly increased water resistance.
A61K 8/40 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant de l'azote
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
The present invention relates to methods of reducing material transfer of cosmetic compositions which include at least one liquid dispersion of an acrylic polymer by incorporating into the cosmetic compositions an amount of a hyperbranched copolymer sufficient to reduce material transfer of the cosmetic composition, wherein the hyperbranched copolymer is a copolymerization reaction product of the monomers dodecenyl succinic acid anhydride, diisopropanol amine and bis-dimethylaminopropyl amine having quaternary terminal groups and at least one liquid dispersion of an acrylic polymer which is a homopolymer or a copolymer of the monomers selected from the group consisting of (meth)acrylic acid, (meth)acrylic esters, (meth)acrylamide and amides of (meth)acrylic acid.
A61K 8/81 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons insaturées carbone-carbone
The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level said metabolites.
A23K 50/10 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les ruminants
A23K 50/30 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les porcs
A23K 50/75 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les oiseaux pour la volaille
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
The present invention relates to a novel use of proline containing dipeptides for evening out as well as brightening the skin tone. These proline containing dipeptides are furthermore particular suitable for improving the skin tone of the cheek under the eyes, on the cheek and the jawline.
A61K 8/55 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant du phosphore
A61Q 19/02 - Préparations pour les soins de la peau pour décolorer ou blanchir la peau chimiquement
7.
METHODS OF MODULATING GASTROINTESTINAL METABOLITES
The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level said metabolites.
A23K 50/10 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les ruminants
A23K 50/30 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les porcs
A23K 50/75 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les oiseaux pour la volaille
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
8.
METHODS OF MODULATING GASTROINTESTINAL METABOLITES
The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level said metabolites.
A23K 50/10 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les ruminants
A23K 50/30 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les porcs
A23K 50/75 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les oiseaux pour la volaille
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
9.
METHODS OF MODULATING GASTROINTESTINAL METABOLITES
The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level said metabolites.
A23K 50/10 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les ruminants
A23K 50/30 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les porcs
A23K 50/75 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les oiseaux pour la volaille
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
10.
POLYMER COMPOSITION AND METHOD OF MAKING A MEDICAL IMPLANT
The invention concerns a polymer composition for making a bone anchoring part of an orthopedic implant for use in repair of damaged cartilage tissue, comprising a biostable thermoplastic polyurethane and 15-70 mass % of micron-sized inorganic particles comprising a biocompatible transition metal compound. It was found that the relatively rigid TPU composition comprising said inorganic particles allows making an anchoring part that can be inserted or press-fitted into a pre-drilled bone hole to form a firm and durable connection to bone tissue, and which may be visualized with for example X-ray or MRI methods. The polymer composition shows favorable properties and enables freedom in designing and making the implant with common techniques like injection molding. In other aspects, the invention relates to methods of making said polymer composition, and to using the polymer composition in making an orthopedic implant comprising a bone anchoring part, like in forming the implant with a multi-component injection molding process comprising a step of molding the bone anchoring part from the polymer composition.
The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level said metabolites.
A23K 50/10 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les ruminants
A23K 50/30 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les porcs
A23K 50/75 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les oiseaux pour la volaille
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
12.
SUCROSE ISOMERASES AS FOOD AND NUTRITIONAL SUPPLEMENTS
Sucrose isomerase is used as a nutritional supplement, or can be mixed in with a powderous food/beverage formulation. When an animal, including a human, consumes sucrose, the sucrose isomerase will act on the sucrose present in the food, and will convert the sucrose to other sugars. This results in lowering of the glycemic index of the food without changing the formulation of the food.
The present invention relates to a new formulation comprising a mixture of lutein and zeaxanthin in a specific ratio, polysorbate and water. The formulation can be used in a variety of products (such food, feed, dietary supplements, pharmaceuticals, or other products).
A23L 5/44 - Adjonction de colorants ou de pigments, p. ex. en combinaison avec des azurants optiques en utilisant des colorants ou des pigments organiques d'origine naturelle, leurs doublons artificiels ou leurs dérivés en utilisant des caroténoïdes ou des xanthophylles
A23L 29/10 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des émulsifiants
14.
DEGRADABLE PARTICLES COMPRISING HIGH LEVELS OF RAPAMYCIN
Disclosed are drug delivery devices, coatings, and microparticles that achieve sufficiently small particle sizes with high loading of Rapamycin. In an embodiment, a balloon comprises a coating on its exterior surface, the coating comprising microparticles having a Dv90 particle size of from 1 to 11 μm, as measured with static laser scattering, the microparticles comprising from 35 to 50 wt % of rapamycin, based on the total weight of the microparticles, and a random copolymer according to Formula (I).
The present invention relates to the use of neutral core human milk oligosaccharides such as in particular lacto-N-(neo)tetraoses as anti-ageing active ingredient as well as the use thereof in topical anti-ageing compositions.
The present invention relates to a new formulation, which comprises a high amount of retinol, which has a defined mixture of cis and trans isomers, in a specific solvent and in the presence of mixed tocopherol.
A61K 31/07 - Composés du rétinol, p. ex. vitamine A
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61Q 19/00 - Préparations pour les soins de la peau
The present invention relates to the use of selected UV filters selected from the group consisting of octocrylene, ethylhexyl salicylate and butyl methoxydibenzoylmethane to reduce the abundance of C. acnes strains in a skin microbiome after UV radiation. Said use is suitable to prevent and or treat the progression of acne, in particular the progression of acne exacerbated by sunscreen application.
A61K 8/40 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant de l'azote
The present invention relates to a method for modulating the level of one or more secondary metabolite(s), and a use for modulating the level of one or more secondary metabolite(s) in the gastrointestinal tract of an animal.
A23K 10/18 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires de micro-organismes vivants
Polyesteramide (PEA) copolymers are disclosed, having structures that include repeating units that contain various monomer residues characterized herein and present in the repeating units at defined ranges of molar equivalents. These copolymers can possess a number of important advantages for providing longer performing glucose sensors and/or for simplifying their design. For example, in vivo modeling has confirmed that these polymers exhibit both decreased collagen deposition and increased neovascularization (angiogenesis). Additional testing has demonstrated favorable oxygen and glucose transport capabilities, as well as other relevant properties.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
A61B 5/1486 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques en utilisant des électrodes enzymatiques, p. ex. avec oxydase immobilisée
The present invention relates to the use of certain 4-amidino benzylamines as ingredient to increase skin firmness and elasticity by increasing type I collagen expression in the skin.
A61K 8/46 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant du soufre
A61Q 19/08 - Préparations contre le vieillissement
21.
COSMETIC COMPOSITION COMPRISING SPECIFIC HYPERBRANCHED COPOLYMERS AND NON-IONIC EMULSIFIERS BEING AN ETHER OR AN ESTER OF (POLY)ETHYLENEOXIDE
The present invention relates to cosmetic skin care compositions which comprise a hyperbranched copolymer of the monomers dodecenyl succinic acid anhydride, diisopropanol amine and bis-dimentheylaminopropyl amine having quaternary terminal groups and at least one non-ionic emulsifier being an ether or an ester of (poly)ethylene glycol.
The present invention relates to an animal feed comprising up to 20% (w/w) yeast single cell protein product, wherein the yeast single cell protein product comprises Saccharomycesales yeast cells, as well as to the use of said animal feed for feeding an animal and/or for increasing body weight of an animal.
A61K 36/064 - Saccharomycetales, p. ex. levure de boulanger
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
A23K 20/147 - Dérivés polymériques, p. ex. peptides ou protéines
A23K 50/80 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les animaux aquatiques, p. ex. pour les poissons, les crustacés ou les mollusques
The present invention relates to a new formulation, which comprises a high amount of retinol, which has a defined mixture of cis and trans isomers, in a specific solvent and in the presence of mixed tocopherol.
The invention relates to a dry extrusion process for preparing a texturized vegetable protein, to a composition comprising rapeseed protein, a legume-derived protein, and a plant-based fiber, to the use of said composition in the preparation of a meat alternative and to meat alternatives.
The present disclosure relates to the production of sialylated Human Milk Oligosaccharides (HMOs), in particular to the biosynthetic production of 3′-sialyllactose (3′SL), and to genetically engineered cells and methods suitable for said production.
C07K 14/24 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant d'Entérobacteriaceae (F), p. ex. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present invention relates to a new formulation, which comprises a high amount of retinol, which has a defined mixture of cis and trans isomers, in a specific solvent and in the presence of mixed tocopherol.
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61Q 19/00 - Préparations pour les soins de la peau
27.
SEPARATION OF HUMAN MILK OLIGOSACCHARIDES FROM A FERMENTATION BROTH
The invention relates to a method for recovery and purification of human milk oligosaccharides (HMOs) from a fermentation broth, comprising the steps of separating the fermentation broth to form a separated HMO-containing stream and a biomass waste stream, purifying the separated HMO-containing stream, concentrating the purified HMO-containing stream, and drying the purified HMO-containing stream to obtain solidified HMO. Moreover, the invention also concerns a human milk oligosaccharide obtained by the inventive method, as well as its use in food, feed, and medical application.
The present disclosure provides a method for increasing production of a polyunsaturated fatty acid, especially eicosapentaenoic acid (EPA), in a microorganism, comprising adjusting the macro-and/or micronutrients during fermentation. The invention includes any culture, biomass, and oil produced by the method.
Methods for sustainably producing a pet food product and the pet food products thereby produced include formulating a pet food product by replacing all or part of fish oil in a pet food product composition with a single microbial source of eicosapentaenoic acid (“EPA”) and docosahexaenoic acid (“DHA”). In a preferred embodiment, the microbial source comprising DHA and EPA derives from a microorganism/microbe of the genus Schizochytrium or Thraustochytrium.
A23K 20/158 - Acides grasGraissesProduits contenant des huiles ou des graisses
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
A23K 50/40 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les animaux carnivores, p. ex. pour les chats ou les chiens
In an embodiment, a polyurethane comprises the residues of i. an aliphatic diisocyanate, ii. an aliphatic diol comprising a poly(ethylene oxide) moiety, iii. an aliphatic diol comprising a polycarbonate moiety, and iv. a chain extender, wherein the polyurethane has a melting temperature of 140° C. or less and has a weight average molecular weight of from 100,000 to 500,000 g/mol. In an embodiment, the polyurethane is substantially devoid of catalyst. In an embodiment, the polyurethane is formed by reactive extrusion. In an embodiment, a medical device comprises the polyurethane and a bioactive agent. The medical devices, methods, and polyurethanes may exhibit benefits in end-product biostability, drug release profile, health and safety, and processing speed or reproducibility.
A61L 31/06 - Matériaux macromoléculaires obtenus autrement que par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
A61L 29/06 - Matériaux macromoléculaires obtenus autrement que par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
C08G 18/12 - Procédés mettant en œuvre un prépolymère impliquant la réaction d'isocyanates ou d'isothiocyanates avec des composés contenant des hydrogènes actifs, dans une première étape réactionnelle utilisant plusieurs composés contenant un hydrogène actif dans le premier stade de la polymérisation
The present invention discloses a LC-PUFA biomass composition which has reduced self-heating propensity and thus requires a lessened packing requirement for shipment. The invention also discloses methods for making such biomass composition.
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
C12N 1/12 - Algues unicellulairesLeurs milieux de culture
The present invention relates to a process for reducing an amount of phospholipids in an oil composition using an enzyme having phospholipase A2 activity.
The present invention is related to a novel process on biological production of lipophilic substances in an oleaginous host cell, particularly Yarrowia lipolytica, comprising modification in the N-glycosylation pathway, leading to higher yield and product purity with further facilitating the overall production process.
C12P 23/00 - Préparation de composés contenant un cycle cyclohexène comportant une chaîne latérale non saturée d'au moins dix atomes de carbone liés par des doubles liaisons conjuguées, p. ex. carotènes
The present disclosure relates to a genetically modified cell capable of utilizing sucrose as energy and carbon source following the expression of a single heterologous enzyme, which upon expression is translocated from the cytosol and which is capable of hydrolysing non-phosphorylated sucrose into fructose and glucose.
The present disclosure relates to a genetically modified cell capable of utilizing sucrose as energy and carbon source following the expression of a single heterologous enzyme, which upon expression is translocated from the cytosol and which is capable of hydrolysing non-phosphorylated sucrose into fructose and glucose.
The identification of efficient enzymes capable of hydrolysing sucrose in its non-modified form, and which on its own enable the cell to utilize sucrose as a, or as the main and/or sole, carbon and/or energy source, i.e., without the need for multi-gene sucrose utilizing systems comprising several other heterologous polypeptides, such as other enzymes and/or transporters, is highly advantageous, since it allows for cost-effective use of sucrose in large scale production processes.
The present invention relates to a composition for aquatic animals comprising as active ingredient 25-hydroxyvitamin D, preferably 25-hydroxy vitamin D3 (25-OH D3). The present invention further relates to the use of 25-hydroxyvitamin D, preferably 25-hydroxyvitamin D3 (25-OH D3), as feed additive for aquatic animals including fish and shrimp. More particular, this invention relates to the use of 25-hydroxyvitamin D, preferably 25-hydroxyvitamin D3 (25-OH D3), for improving feed utilization and growth and performance parameters of the animals, such as the feed conversion ratio (FOR). Immunity, protein efficiency ratio (PER), specific growth rate (SGR), final body weight, feed efficiency (FE), nutrient utilization, body protein content, and/or carcass yield and/or for increasing levels of Vitamin D, preferably Vitamin D3, in the blood of aquatic animals.
A23K 40/25 - Mise en forme ou traitement des produits alimentaires pour animaux par extrusion
A23K 40/30 - Mise en forme ou traitement des produits alimentaires pour animaux par encapsulationMise en forme ou traitement des produits alimentaires pour animaux par revêtement
A23K 50/80 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les animaux aquatiques, p. ex. pour les poissons, les crustacés ou les mollusques
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The present invention relates to a method of reducing methane emissions in ruminants, said method encompassing treating pre-/young ruminants with 3-nitrooxypropanol.
Methods of feeding animals are disclosed whereby feed additives are provided that modulate the gut microbiome to prevent or treat dysfunctions in a gastrointestinal barrier. The present disclosure further relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to prevent or treat infections.
The present invention relates to a meat analogue product comprising a texturized vegetable protein, a binder, a flavor and 0.5 to 10% (w/w) of a rapeseed protein isolate comprising napins and cruciferins, wherein the rapeseed protein isolate comprising napins and cruciferins is not texturized.
Synthetic biopolymers are disclosed, which can be engineered in terms of both their amino acid sequences and post-synthesis treatments to which they are subjected, to achieve desired gelation characteristics, particularly upon being exposed to physiological temperature (e.g., 37° C.). These synthetic biopolymers are therefore useful for injectable or implantable compositions for tissue repair, such as for bone void filler compositions. Examples of synthetic biopolymers are synthetic elastin-like polypeptides (ELPs) having polypeptide sequences with functional oligopeptide blocks that may include one or more hydrophobic blocks, one or more aggregation-enhancing blocks, and one or more β-sheet formation-inducing blocks. Optionally, one or more biomineralizing blocks may be present, to promote bone repair, growth, and/or strengthening.
A61L 27/46 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire avec des charges inorganiques contenant du phosphore
Methods of making a composite fabric for use in or as a medical implant component are disclosed whereby the method includes the steps of providing a textile comprising at least one strand having titer of 2-250 dtex and comprising fibers made from a biocompatible and biostable synthetic polymer; determining locations on the textile where a cut is to be made for an intended use of the textile; optionally pretreating the textile at least at the determined locations on at least one side of the textile with a high-energy source to activate the surface; solution coating the textile at least at a determined location with a coating composition comprising a biocompatible and biostable polyurethane elastomer and a solvent for the polyurethane; removing the solvent from the coated textile; and laser cutting the coated textile as obtained at least a one coated location with an ultra-short pulse laser; to result in a composite biotextile wherein polyurethane is present in an amount of 2.5-90 mass % based on composite biotextile and polyurethane is present at least at a laser-cut edge.
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
A61L 27/26 - Mélanges de matériaux macromoléculaires
D06N 3/00 - Cuir artificiel, toile cirée ou matériau similaire obtenu par enduction de nappes fibreuses avec une substance macromoléculaire, p. ex. avec des résines, du caoutchouc ou leurs dérivés
D06N 3/14 - Cuir artificiel, toile cirée ou matériau similaire obtenu par enduction de nappes fibreuses avec une substance macromoléculaire, p. ex. avec des résines, du caoutchouc ou leurs dérivés avec des composés macromoléculaires obtenus autrement que par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone avec des polyuréthanes
41.
COMPUTER-BASED METHOD FOR DETERMINING A SUNSCREEN COMPOSITION COMPRISING A PLURALITY OF UV FILTER SUBSTANCES
A computer-based method for determining a sunscreen composition comprising a plurality of UV filter substances, comprises the steps of selecting at least one constraint for at least one characteristic of the composition to be determined (step 30), the at least one constraint comprising a sunscreen performance target; selecting an optimization objective from a plurality of optimization objectives (step 50); and automatically determining the sunscreen composition as a composition of filter substances from a set of filter substances (step 100), the composition meeting the at least one constraint and being optimized with respect to the selected optimization objective. The automatic determination comprises the steps of generating a plurality of candidate compositions, determining a sunscreen performance of the candidate compositions using a performance simulation tool and comparing the determined sunscreen performance of the candidate compositions with the sunscreen performance target. The method allows for an automatic determination of an optimum sunscreen composition based on constraints and objectives, thus avoiding manual trial and error methods that are lengthy and do not always lead to the optimal result.
Disclosed embodiments concern a composition comprising mannan-derived oligosaccharides orycast cell wall product and vitamin C. vitamin E, vitamin D3, and selenium. The disclosedembodiments further concern a method of administering the above composition as a feedadditive to supplement the feed of. farm animals. particularly for sows and piglets. The disclosedmethod is for promoting the immunity of pigs.
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
C07C 29/42 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par des réactions augmentant le nombre d'atomes de carbone avec formation de groupes hydroxyle, ces groupes pouvant être produits par l'intermédiaire de dérivés de groupes hydroxyle, p. ex. du dérivé O-métal par réactions avec des aldéhydes ou des cétones avec des composés contenant des liaisons triples carbone-carbone, p. ex. avec des alcynes métalliques
The present invention provides a method for reducing ammonia emission of animals comprising administering to the animals one or more proteolytic enzymes, i.e., proteases. The present invention also provides a feed composition suitable for the above methods and use thereof.
The present invention relates a variant polypeptide having geranylgeranyl pyrophosphate synthase activity, which variant polypeptide comprises an amino acid sequence which, when aligned with a geranylgeranyl pyrophosphate synthase comprising the sequence set out in SEQ ID NO: 1, comprises at least one substitution of an amino acid residue corresponding to any of amino acids at positions 92, 100 or 235 said positions being defined with reference to SEQ ID NO: 1 and wherein the variant has one or more modified properties as compared with a reference polypeptide having geranylgeranyl pyrophosphate synthase activity. A variant polypeptide of the invention may be used in a recombinant host for the production of steviol or a steviol glycoside.
C12P 15/00 - Préparation de composés contenant au moins trois carbocycles condensés
C12P 19/56 - Préparation d'O-glucosides, p. ex. glucosides avec un atome d'oxygène du radical saccharide lié directement à un système cyclique condensé d'au moins trois carbocycles, p. ex. daunomycine, adriamycine
The present invention relates to novel compositions comprising mixtures of cis and trans isomers of retinol, particularly with a cis/trans ratio of less than 1:100, as well as the use of said compositions for preservation.
A01N 31/04 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques de l'oxygène ou du soufre l'atome d'oxygène ou de soufre étant lié à une chaîne latérale aliphatique d'un système cyclique carbocyclique
A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
A61Q 17/00 - Préparations protectricesPréparations employées en contact direct avec la peau pour protéger des influences extérieures, p. ex. des rayons du soleil, des rayons X ou d'autres rayons nuisibles, des matériaux corrosifs, des bactéries ou des piqûres d'insectes
The present invention relates to a new delivery system for Vitamin C (also known as ascorbic acid and ascorbate) for the release large intestine. These nutritional ingredients are useful for gut and metabolic health in monogastric animals (such as swine and poultry as well as fish), especially in humans.
The present invention relates to use of oligosaccharide preparations to increase average body weight and/or to decrease feed conversion ratio and/or to increase average body weight gain of a bird, and to oligosaccharide preparations for use in treatment, amelioration and/or prophylaxis of a bird vaccinated against coccidiosis.
The present invention relates to a new coating system useful for coating particles, which comprise an active ingredient. Such coated particles, when consumed, do show a controlled release in the human or animal body.
The present invention relates to a ready to mix composition comprising 30 to 60 wt. % pea and rapeseed protein, 5 to 25 wt. % dietary fiber, 0 to 15 wt. % creaming agent, 1 to 15 wt. % flavor and 0.1 to 5 wt. % hydrocolloid, wherein the ratio of pea and rapeseed protein is within the range of 80:20 to 20:80.
A23L 29/238 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des agents gélifiants ou épaississants d'origine végétale à partir de graines, p. ex. gomme de caroube ou gomme de guar
The present invention relates to cosmetic composition comprising the UV-filter Ensulizole, an ester of a fatty acid and dextrin and a mixture of branched and linear saturated C15-C19, wherein said mixture comprised primarily branched saturated C15-C19. This cosmetic composition shows an increased water resistance of the sun protecting factor.
A61K 31/23 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine d'acides ayant un groupe carboxyle lié à une chaîne d'au moins sept atomes de carbone
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A61K 31/222 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine avec des composés ayant des groupes aromatiques, p. ex. dipivéfrine, ibopamine
C07C 403/20 - Dérivés du cyclohexane ou d'un cyclohexène, comportant une chaîne latérale avec une partie non saturée d'au moins quatre atomes de carbone en ligne, ladite partie étant directement attachée aux cycles cyclohexane ou cyclohexène, p. ex. vitamine A, bêta-carotène, bêta-ionone ayant des chaînes latérales substituées par des groupes carboxyle
C07D 333/48 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant un atome de soufre comme unique hétéro-atome du cycle non condensés avec d'autres cycles substitués sur l'atome de soufre du cycle par des atomes d'oxygène
54.
COMPOSITE SHEETS AND MEDICAL IMPLANTS COMPRISING SUCH SHEETS
Disclosed herein are composite sheets and prosthetic medical devices formed therefrom. In an embodiment, a composite sheet has a thickness of 25-250 μm and comprises 10-70 mass %, based on the total mass of the composite sheet, of a knit fabric having thickness of 15-225 μm and comprising strands of 2-50 dtex, the strands comprising biocompatible polymer fibers, the strands comprising biocompatible polymer fibers, wherein the fabric comprises a thickness in a plurality of first locations, and pores in a plurality of second locations; and 30-90 mass %, based on the total mass of the composite sheet, of a polyurethane coating, wherein the polyurethane coating coats the fabric and fills the pores of the fabric such that the composite sheet is substantially impermeable to water.
A61L 27/48 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire avec des charges macromoléculaires
B32B 5/02 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par les caractéristiques de structure d'une couche comprenant des fibres ou des filaments
B32B 27/12 - Produits stratifiés composés essentiellement de résine synthétique adjacente à une couche fibreuse ou filamenteuse
B32B 27/40 - Produits stratifiés composés essentiellement de résine synthétique comprenant des polyuréthanes
The present invention relates to novel compositions comprising a retinoid mixture of cis and trans isomers of a retinyl ester, particularly retinyl acetate, with a cis/trans ratio of less than 0.03 as well as the use thereof for the treatment, prevention and lessening of the symptoms of diseases and conditions which can be treated with 5-HT2B serotonin receptor antagonists, including but not limited to diseases or conditions selected from migraine headaches, anxiety, ocular hypotension, heart valve disease, irritable bowel syndrome, and MDMA (commonly called “ecstasy”) abuse.
A61K 31/222 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine avec des composés ayant des groupes aromatiques, p. ex. dipivéfrine, ibopamine
A23L 2/84 - Clarification ou affinage des boissons non alcooliséesÉlimination des matières non désirées utilisant des micro-organismes ou un matériau biologique, p. ex. enzymes
Disclosed herein are compositions produced from microorganisms that are capable of producing high levels of docosapentaenoic acid (DPA(n-3)), and methods for producing the compositions. The invention is further directed to microbial strains and derivatives therefrom, biomasses, and microbial oils.
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 35/68 - Protozoaires, p. ex. flagelles, amibes, sporozoaires, plasmodium ou toxoplasma
The present invention relates to water-soluble or water-dispersible granules that are obtainable by continuous melt granulation. The granules comprise at least one binder, at least one filler and at least one active ingredients. Torque overload may be avoided when using a combination of the herein disclosed filler (e.g. mannitol or an HIMO) and binder (e.g. sorbitol).
A61K 31/525 - Iso-alloxazines, p. ex. riboflavines, vitamine B2
A61K 31/593 - Dérivés du 9,10-séco-cholestane, p. ex. cholécalciférol, vitamine D3
A61K 31/714 - Cobalamines, p. ex. cyanocobalamine, vitamine B12
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
59.
HIGH POTENCY GRANULES OBTAINABLE BY CONTINUOUS MELT GRANULATION
The present invention relates to water-soluble or water-dispersible granules that comprise a binder, a filler and an active ingredient. Preferred granules of the invention are obtained by continuous melt granulation of a mixture that comprises 65-70 weight-% active ingredient. 15-25 weight-% filler and 5-15 weight-% binder, based on the total weight of the mixture. Ascorbic acid and edible salts thereof are the preferred active ingredients.
A23P 10/25 - Agglomération ou granulation par extrusion ou par compression, p. ex. par des petits trous, des tamis ou entre des surfaces
A23L 29/30 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sirops d'hydrate de carboneAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sucresAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des alcools de sucre, p. ex. du xylitolAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des hydrolysats d'amidon, p. ex. de la dextrine
The present application relates to a texture improver. The texture improver comprises curdlan and rapeseed protein at a weight ratio of 1:9 to 9:1. When used in food, particularly in a meat product or a plant-based meat product, the texture improver can remarkably improve the texture and taste of the product, and meets clean food label requirements.
The present invention relates to water-soluble or water-dispersible granules that are obtainable by continuous melt granulation. In an embodiment, the granules comprise at least one binder, at least one filler and microcapsules that encapsulate fat-soluble active ingredients.
The present invention relates to improved formulations of propandiol mononitrate and derivatives thereof as well as to the methods for production of such formulations.
A23K 20/105 - Composés aliphatiques ou alicycliques
A23K 10/35 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons à base de pommes de terre
A23K 20/28 - Silicates, p. ex. perlites, zéolites ou bentonites
A23K 30/00 - Procédés spécialement adaptés à la conservation des matières servant à la fabrication des produits alimentaires pour animaux
A23K 40/10 - Mise en forme ou traitement des produits alimentaires pour animaux par agglomérationMise en forme ou traitement des produits alimentaires pour animaux par granulation, p. ex. fabrication de poudres
63.
IDENTIFICATION OF AN alpha-1,2-FUCOSYLTRANSFERASE FOR THE IN VIVO PRODUCTION OF PURE LNFP-I
The present disclosure discloses the identification and introduction of a specific heterologous gene (denoted as smob), which encodes an α-1,2-fucosyltransferase, into an LNT production strain to produce LNFP-I in particular.
The present disclosure discloses the identification and introduction of a specific heterologous gene (denoted as smob), which encodes an α-1,2-fucosyltransferase, into an LNT production strain to produce LNFP-I in particular.
The smob gene originates from the organism Sulfuriflexus mobilis (https://www.dsmz.de/collection/catalogue/details/culture/DSM-102939), which is a sulfur-oxidizing bacterium isolated from a brackish lake sediment.
The present disclosure discloses the identification and introduction of a specific heterologous gene (denoted as smob), which encodes an α-1,2-fucosyltransferase, into an LNT production strain to produce LNFP-I in particular.
The smob gene originates from the organism Sulfuriflexus mobilis (https://www.dsmz.de/collection/catalogue/details/culture/DSM-102939), which is a sulfur-oxidizing bacterium isolated from a brackish lake sediment.
FIG. 1 should accompany the abstract.
C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p. ex. hyaluronidase, invertase, amylase
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present disclosure relates to the field of food. Herein disclosed is a method for preparing a non-animal protein food product or a cultured meat food product comprising adding a lactase protein preparation to an ingredient used in the preparation of said food product and processing the obtained lactase protein preparation and ingredient composition into a non-animal protein food product or a cultured meat food product.
A23J 3/20 - Protéines à partir de micro-organismes ou à partir d'algues unicellulaires
A23C 20/02 - Succédanés du fromage ne contenant ni constituants du lait, ni caséinate, ni lactose, en tant que sources de matières grasses, de protéines ou d'hydrates de carbone
The present disclosure relates to the production of oligosaccharides, especially Human milk Oligosaccharides (HMOs) using a genetically engineered cell which has decreased or total loss of function of phosphoglycerol transferase I and II and/or phosphoethanolamine transferase and/or glucans biosynthesis protein C to reduce oligosaccharide by-products and/or increase oligosaccharide production.
Disclosed herein are processes for obtaining a microbial oil comprising one or more polyunsaturated fatty acids (PUFAs) from one or more microbial cells by lysing the cells to form a lysed cell composition, treating the lysed cell composition to form an oil-containing emulsion and then recovering the oil from the oil-containing emulsion. Further disclosed herein is microbial oil comprising one or more PUFAs that is recovered from microbial cells by at least one process described herein.
The present invention relates to industrial animal production. In particular the present invention relates to a method of raising a group of animals, and a method of determining analytes, in egg yolk or in the blood of an animal by ex vivo analysis of blood and/or yolk samples.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/82 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des vitamines
G01N 33/84 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des composés inorganiques ou le pH
The disclosure provides a recombinant cell capable of producing a steviol glycoside, wherein the cell comprises a nucleic acid coding for a variant of a parent polypeptide, wherein the variant has steviol glycoside transport mediating activity, wherein the variant comprises an amino acid sequence which, when aligned with the amino acid sequence of the parent polypeptide, comprises at least one modification of the amino acid residue corresponding to any of the amino acids in the amino acid sequence of the parent polypeptide, wherein the variant has an improved ability to produce rebaudioside M and optionally other steviol glycosides extracellularly if compared with the parent polytpeptide when measured under the same conditions.
C07K 14/39 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de champignons provenant de levures
C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
C12P 19/56 - Préparation d'O-glucosides, p. ex. glucosides avec un atome d'oxygène du radical saccharide lié directement à un système cyclique condensé d'au moins trois carbocycles, p. ex. daunomycine, adriamycine
69.
HUMAN MILK OLIGOSACCHARIDES IN CLEANSING COMPOSITION
The present invention relates to cleansing compositions comprising certain soaps and human milk oligosaccharides as well as to a method of increasing the foaming properties of cleansing compositions comprising at least one surfactant by incorporation of one or more human milk oligosaccharides into said cleansing composition.
The present invention relates to compositions comprising at least one human milkoligosaccharide selected from the group consisting of 2′-fucosyllactose, difucosyllactose and/or lacto-N-tetraose as an anti-microbial agent against Cutibacterium acnes (C. acnes) as well as the use thereof in a regimen to prevent and/or treat acne comprising the steps of topically administering a composition comprising said human milk oligosaccharide(s) to the skin of a subject with acne/acne prone skin followed by topically administering a composition comprising one or more non-pathogenic live bacterial C. acnes strains.
The invention relates to an extrusion apparatus for the continuous production of solid food supplements, feed additives or pharmaceutical preparations, which comprise nutritional or pharmaceutical actives homogeneously dispersed in a carrier material matrix. The invention also relates to a method for the production of such preparations by extrusion.
A23P 10/25 - Agglomération ou granulation par extrusion ou par compression, p. ex. par des petits trous, des tamis ou entre des surfaces
B29C 48/00 - Moulage par extrusion, c.-à-d. en exprimant la matière à mouler dans une matrice ou une filière qui lui donne la forme désiréeAppareils à cet effet
B29C 48/04 - Moulage par extrusion, c.-à-d. en exprimant la matière à mouler dans une matrice ou une filière qui lui donne la forme désiréeAppareils à cet effet caractérisées par la forme à l’extrusion de la matière extrudée en forme de particules
B29C 48/88 - Traitement thermique de l’écoulement de matière extrudée, p. ex. refroidissement
B29K 105/00 - Présentation, forme ou état de la matière moulée
73.
A METHOD AND SYSTEM FOR DETERMINING A QUANTITATIVE COMPOSITION RATIO OF A MICROBIAL STRAIN MIXTURE FOR USE IN A FERMENTATION PROCESS
A method of determining a quantitative composition ratio of a microbial strain mixture for use in a fermentation process. The method includes repeatedly performing method cycles, each method cycle comprising the steps of: selecting a set of plurality of microbial strain mixtures having different quantitative composition ratios; concurrently performing fermentation processes for each selected microbial strain mixture; determining, for each of the fermentation processes, at least one performance indicator of the microbial strain mixture; and providing the at least one performance indicator for each of the fermentation processes to a statistical model which is configured to optimize a predefined objective function, wherein the statistical model is configured to determine, based on said determined performance indicators, a subsequent set of plurality of microbial strain mixtures with different quantitative composition ratios for selection in a next cycle.
A23C 9/123 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes ne comportant que des micro-organismes de la famille des lactobactériacéesYoghourt
Disclosed herein are devices and methods for processing biologic tissues, such as adipose tissue or whole blood, via centrifugation, An annular cavity is present, typically at the widest interior point of a rotatable chamber. The device is operable such that a sample of biologic tissue present in the rotatable chamber can be stratified into at least two constituent layers as a function of the differing specific gravities of the constituents and at least a portion of one of the constituent layers captured in the annular cavity.
B04B 1/02 - Centrifugeurs à tambours rotatifs à parois pleines pour la séparation de mélanges essentiellement liquides contenant ou non des particules solides sans cloisons intérieures
B04B 1/14 - Centrifugeurs à tambours rotatifs à parois pleines pour la séparation de mélanges essentiellement liquides contenant ou non des particules solides à orifices d'évacuation dans le plan du plus grand diamètre du tambour à évacuation cyclique
B04B 3/00 - Centrifugeurs à tambours rotatifs dans lesquels les particules ou les corps solides sont séparés par la force centrifuge et simultanément par tamisage ou filtration
76.
HUMAN MILK OLIGOSACCHARIDES IN SULFATE-FREE CLEANSING COMPOSITIONS
The present invention relates to sulfate-free cleansing compositions comprising at least one zwitterionic surfactant and at least one human milk oligosaccharide as well as to a method of increasing the foaming properties of cleansing compositions comprising at least one surfactant by incorporation of one or more human milk oligosaccharides into said cleansing composition.
Infant formulae with a very low level of arsenic are obtained by selecting the components of the infant formula very carefully. For manufacturing infant formulae that comprise less than 95 parts per billion (ppb) of arsenic, it is preferred to use human milk oligosaccharides (HMOs) that have been isolated from a fermentation brth without using activated carbon in the last purification step. The preferred HMO is 2′-O-fucosyllactose.
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
The present invention relates to a compound thickener comprising rhamsan gum and gellan gum. In the compound thickener, rhamsan gum accounts for 50%-95% of the total weight of rhamsan gum and gellan gum. The combination of rhamsan gum and gellan gum in the compound thickener produces a synergistic effect, and its viscosity is remarkably improved. The compound thickener can be applied to products such as foods, beverages, pharmaceutical products, and personal care products, and when the compound thickener is applied as a gelling agent in soft capsule shells, the shell strength and the shell elasticity are better.
A process for the preparation of a fermented milk product comprising the steps of: —providing a milk base comprising glucose and fructose; and —fermenting the milk base in the presence of a lactic acid bacterial strain and a glucose-fructose oxidoreductase enzyme.
A23C 9/12 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes
A23C 9/123 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes ne comportant que des micro-organismes de la famille des lactobactériacéesYoghourt
Compositions are formed of a compressed mixture which includes a powderous formulation of a carrier and 3-nitrooxypropanol or derivatives thereof as an active ingredient, and a gluten. The composition remains intact in water after 24 hours.
The present invention relates to a cereal flour-based dough comprising at least 50 wt. % cereal flour, based on the dry weight of the cereal flour-based dough, and rapeseed protein, wherein said rapeseed protein is present in an amount between 0.01 and 15 wt. %, based on the weight of the cereal flour in the cereal flour-based dough, wherein the cereal flour has a gluten content of 5-20 wt. %.
This invention relates to a method of producing mixtures of various human milk oligosaccharides (HMOs) with unique HMO blend profiles, consisting predominantly of LNFP-I and LNT and of other HMOs in less significant amounts. The less abundant HMOs might be 2′-FL, LNT-II or DFL. The strategies for achieving specific HMO blends include strain engineering and fermentation methods.
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The present disclosure relates to a method for the production of a human milk oligosaccharide (HMO) blend with LNFP-I and 2′-FL as the predominant HMO's, the method comprising the steps of providing a genetically engineered cell, which comprises a heterologous β-1,3-N-acetyl-glucosaminyltransferase protein, a heterologous β-1,3-galactosyltransferase protein, a heterologous α-1,2-fucosyltransferase protein, and expresses functionally the colanic acid gene cluster, comprises a native or heterologous regulatory or episomal element for controlling the expression of the proteins and optionally express a heterologous sugar transporter, and culturing the cell in a suitable cell culture medium to express said proteins and to produce an HMO blend.
A feed control system and related methods for a heterologous product, such as a human milk oligosaccharide, fermentation system are disclosed. The feed control system comprises a feed controller. The feed controller comprises a processor and an interface. The processor is configured to obtain a biomass content in a fermentation broth. The processor is configured to determine a carbon input parameter based on the biomass content. The processor is configured to control a carbon input to the fermentation broth according to the carbon input parameter.
C12M 1/36 - Appareillage pour l'enzymologie ou la microbiologie comportant une commande sensible au temps ou aux conditions du milieu, p. ex. fermenteurs commandés automatiquement
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
Methods to improve retention of propanediol mononitrate and derivatives thereof in a powderous formulation comprising the propane diol mononitrate and silica include forming a uniform mixture of (i) the powderous formulation and (ii) at least one inorganic carbonate in an amount to achieve a weight ratio of the at least one inorganic carbonate to the powderous formulation of at least 1:1. The at least one inorganic carbonate is present in an amount such that a weight ratio (w/w) in the uniform mixture of the at least one inorganic carbonate to the compound of formula (1) is at least 50:1 sufficient to achieve storage stability of the uniform mixture such that retention of the compound of formula (I) is improved by at least 10% when stored in a closed container for 1 month at 25° C. and 50% relative humidity as compared to a mixture which does not include the at least one inorganic carbonate.
The present invention relates to a process for fermenting Yarrowia in a bioreactor, comprising cultivating Yarrowia in a medium, and adding a feed comprising formic acid and a sugar to the medium in a molar ratio of formic acid to sugar of 1 to 13 mol formic acid/mol monosaccharide.
C12M 1/36 - Appareillage pour l'enzymologie ou la microbiologie comportant une commande sensible au temps ou aux conditions du milieu, p. ex. fermenteurs commandés automatiquement
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
The present invention relates to the manufacture of gamma, delta-unsaturated ketones from tertiary vinyl carbinols and vinylic ethers or ketals using an organic tertiary or quaternary ammonium salt as catalyst.
C07C 45/51 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés par pyrolyse, réarrangement ou décomposition
B01J 31/02 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques
The present invention relates to a composition comprising rapeseed protein, a vegetable fat having a solid fat content of 20-90% (w/w) at 5° C., sucrose and water, wherein the amount of rapeseed protein is from 0.1-10% (w/w), wherein the amount of vegetable fat is from 1-40% (w/w) and wherein the amount of sucrose is from 1-25% (w/w).
A23G 9/38 - Desserts glacés, p. ex. confiseries glacées, glacesMélanges correspondants caractérisés par la composition contenant des peptides ou des protéines
A23D 7/005 - Compositions à base d'huiles ou de graisses comestibles contenant une phase aqueuse, p. ex. margarines caractérisées par des ingrédients autres que des triglycérides d'acides gras
A23G 9/34 - Desserts glacés, p. ex. confiseries glacées, glacesMélanges correspondants caractérisés par la composition caractérisés par les hydrates de carbone utilisés, p. ex. des polysaccharides
Methods of feeding animals are disclosed wherein providing feed additives are provided that modulate the gut microbiome to improve the health, nutrition, and growth performance. Methods of modulating the microbial species present in the gastrointestinal tract of an animal are also disclosed. Such modulation includes, for example, modulating the level or function of microbial species.
The invention relates to a method for recovery and purification of a neutral or sialylated human milk oligosaccharide (HMO) from a fermentation broth, comprising the steps of separating the fermentation broth to form a separated HMO-containing stream and a biomass waste stream, purifying the HMO-containing stream by nanofiltration, purifying the HMO-containing stream with an acidic cation exchange resin, concentrating the purified HMO-containing stream, and drying the purified HMO-containing stream to obtain a solidified neutral or sialylated HMO. Moreover, the invention also concerns a neutral or sialylated human milk oligosaccharide obtained by the inventive method, as well as its use in food, feed, and medical application.
C07H 3/06 - Oligosaccharides, c.-à-d. saccharides comportant de trois à cinq radicaux saccharide liés entre eux par des liaisons glucosidiques
B01J 47/014 - Procédés d'échange d'ions en généralAppareillage à cet effet dans lesquels les propriétés d’adsorption de l’échangeur d’ions sont utilisées, p. ex. récupération de protéines ou de composés macromoléculaires
C07H 1/08 - SéparationPurification à partir de produits naturels
91.
SEPARATION OF HUMAN MILK OLIGOSACCHARIDES FROM A FERMENTATION BROTH
The invention relates to a method for recovery and purification of a neutral or sialylated human milk oligosaccharide (HMO) from a fermentation broth, comprising the steps of separating the fermentation broth to form a separated HMO-containing stream and a biomass waste stream, purifying the HMO-containing stream by ultrafiltration using an ultrafiltration membrane having a MWCO of 500 Da to 5 kDa, purifying the HMO-containing stream by nanofiltration, concentrating the purified HMO-containing stream, and drying the purified HMO-containing stream to obtain a solidified neutral or sialylated HMO. Moreover, the invention also concerns a neutral or sialylated human milk oligosaccharide obtained by the inventive method, as well as its use in food, feed, and medical application.
The present invention is related to a novel process for production of retinyl acetate in a host cell, particularly oleaginous yeast such as e.g. Yarrowia, wherein the product purity could be increased with reduction of unwanted side-products. Particularly, the novel process comprises fermentation in the presence of ethanol, such as e.g. in a fed-batch fermentation process. Such process is especially useful in a biotechnological process for production of vitamin A.
C12P 23/00 - Préparation de composés contenant un cycle cyclohexène comportant une chaîne latérale non saturée d'au moins dix atomes de carbone liés par des doubles liaisons conjuguées, p. ex. carotènes
This invention relates to a method of producing one or more human milk oligosaccharides (HMOs), in particular LNT and/or LNnT, in a genetically engineered cell comprising an enhanced oligosaccharide transport capability. The genetically modified cell comprises a series of genetic modification which enable the production of one or more HMO(s), and a series of genetic modification that enhances the transport of lactose and produced HMO(s).
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
The invention relates to an improved process for the manufacture of bis-resorcinyl triazines of formula (I), wherein R1 is hydrogen, C1-C18alkyl or C2-C18alkenyl and R2 is C1-C18alkyl or C2-C18alkenyl.
The invention relates to an improved process for the manufacture of bis-resorcinyl triazines of formula (I), wherein R1 is hydrogen, C1-C18alkyl or C2-C18alkenyl and R2 is C1-C18alkyl or C2-C18alkenyl.
C07D 251/24 - Composés hétérocycliques contenant des cycles triazine-1, 3, 5 non condensés avec d'autres cycles comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des atomes d'hydrogène ou de carbone liés directement à au moins un atome de carbone du cycle à trois atomes de carbone du cycle
The present invention relates to a method for cultivating a microorganism, comprising the steps of
(i) adding into a first bioreactor a medium and an inoculum comprising the microorganism and producing a fermentation broth in fed-batch culture; and
(ii) adding into a second bioreactor a second medium and part of the fermentation broth from step (i) and producing a second fermentation broth in a second fed-batch culture; and
(iii) adding into a next bioreactor a next medium and a part of the fermentation broth from step (ii), and producing a next fermentation broth in a next fed-batch culture,
wherein a feed is introduced into the first, second and next bioreactor.
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/36 - Appareillage pour l'enzymologie ou la microbiologie comportant une commande sensible au temps ou aux conditions du milieu, p. ex. fermenteurs commandés automatiquement
C12N 9/18 - Hydrolases agissant sur les esters d'acides carboxyliques
C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
C12N 9/42 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons bêta-glucosidiques-1, 4, p. ex. cellulase
C12P 7/10 - Éthanol en tant que produit chimique et non en tant que boisson alcoolique préparé comme sous-produit, ou préparé à partir d'un substrat constitué par des déchets ou par des matières cellulosiques d'un substrat constitué par des matières cellulosiques
The present invention relates to the field of molecular biology and cell biology. More specifically, the present invention relates to a CRISPR transient expression construct (CTEC) for a genome editing system.
The present invention relates to sunscreen compositions containing bis-ethylhexyloxyphenol methoxy phenyl triazine (BEMT) and at least one film forming agent selected from the group consisting of citrate crosspolymers and polyamides in combination with an alkandiol with the proviso that the composition is free of octocrylene, ethylhexyl triazone, diethylamino hydroxy benzoyl hexyl benzoate and ethylhexyl methoxycinnamate. Said compositions exhibit a reduced soaping effect and thus a more appealing skin feel and look.
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
The invention concerns a ballistic-resistant molded article having an areal density of at least 7.0 and at most 12.0 kg/m2, comprising a consolidated stack of fibrous monolayers, each fibrous monolayer containing unidirectionally aligned high tenacity polyethylene filaments, the polyethylene filaments having a tenacity of at least 3.5 N/tex, wherein the molded article comprises between 5.0 and 20 wt % of a binder, wherein the molded article comprises at least 330 of said fibrous monolayers. The invention also relates to a ballistic-resistant sheet suitable to manufacture the molded article, wherein said ballistic-resistant sheet has an areal density of between 6 and 30 g/m2 per polyethylene filament monolayer present in the ballistic-resistant sheet. The invention further relates to a ballistic-resistant molded article whit improved performance when shot under an angle of 30 degree.
F41H 5/04 - Structure des plaques composées de plus d'une couche
B32B 5/26 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par la présence de plusieurs couches qui comportent des fibres, filaments, grains ou poudre, ou qui sont sous forme de mousse ou essentiellement poreuses une des couches étant fibreuse ou filamenteuse un autre couche également étant fibreuse ou filamenteuse
100.
PURIFICATION OF SPECIFIC TRIPEPTIDE BY ACIDIFICATION
The present invention relates to purification of a tripeptide of formula (I). By using said method, the tripeptide of formula (I) is obtained in a very pure form and due to this effect the purified tripeptide can be used in a variety of cosmetic and pharmaceutic compositions which are not accessible for the respective unpurified tripeptide.
The present invention relates to purification of a tripeptide of formula (I). By using said method, the tripeptide of formula (I) is obtained in a very pure form and due to this effect the purified tripeptide can be used in a variety of cosmetic and pharmaceutic compositions which are not accessible for the respective unpurified tripeptide.
brevets
